In this study, we demonstrated an important role of pEGFR upregulation in Akt inhibitor resistance, and Gefitinib treatment may represent a potential therapeutic strategy for breast cancer patients with acquired resistance to Akt inhibitors. The gene discussed is AKT1; the disease is breast carcinoma.